AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is currently recruiting participants for a Phase II study titled An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. The study aims to assess the effectiveness and safety of new drug combinations in treating advanced gastric or gastroesophageal junction adenocarcinoma.
The study involves several experimental treatments, including combinations of drugs such as Volrustomig, Rilvegostomig, AZD0901, and AZD7789, which are designed to target specific cancer pathways and improve patient outcomes.
This interventional study is non-randomized and follows a parallel assignment model with no masking, focusing primarily on treatment. It aims to enroll approximately 240 participants across six substudies.
The study officially began on January 16, 2023, with its primary completion and estimated study completion dates set for June 27, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
For investors, AstraZeneca’s ongoing research into novel cancer treatments could enhance its market position and influence stock performance positively, especially in the competitive oncology sector. The study’s progress and outcomes will be closely watched by stakeholders.
The study is ongoing, with further details available on the ClinicalTrials portal.